ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer

SIMPLE SUMMARY: Different combination therapies are being investigated for the treatment of triple-negative breast cancer (TNBC). Dasatinib is one such drug that targets the Src pathway to kill cancer cells. However, dasatinib treatment can also increase the expression of a different biomarker calle...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ziqi, Belitzky, Erika, Blaha, Ondrej, Cavaliere, Alessandra, Katz, Samantha R., Aboian, Mariam, Melegari, Lindy, Rajabimoghadam, Khashayar, Kurpiewski, Stephen, Zhu, Xiaohua, Marquez-Nostra, Bernadette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001369/
https://www.ncbi.nlm.nih.gov/pubmed/36900378
http://dx.doi.org/10.3390/cancers15051589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001369/
https://www.ncbi.nlm.nih.gov/pubmed/36900378
http://dx.doi.org/10.3390/cancers15051589

Ejemplares similares